Internal Medicine, Hematology & Oncology · Covington, LA
NPI
1528023843
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1203 S Tyler St Ste 230
Covington, LA, 70433
Phone (985) 892-9090
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.0M
238,778 services
Medicare patients, 2024
494
Average age 74
Drug cost, 2024
$5.4M
1,890 prescriptions
Company payments, 2025
$2,913
From 38 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jack E Saux III was code J9267 (injection, paclitaxel, 1 mg), 17,016 times for 11 patients. In total Jack E Saux III billed 238,778 services in 121 codes, and Medicare paid $4.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9267 Injection, paclitaxel, 1 mg | Office | 17,016 | 11 | $0.08 | $1,390 |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 16,830 | 14 | $0.26 | $4,459 |
| Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 7,970 | 11 | $20.62 | $164K |
| J0897 Injection, denosumab, 1 mg | Office | 6,780 | 22 | $20.62 | $140K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 6,600 | 12 | $36.75 | $243K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,400 | 26 | $15.08 | $51K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,260 | 29 | $0.09 | $202 |
| 36415 Venipuncture Blood Collection | Office | 1,646 | 321 | $8.51 | $14K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,596 | 26 | $0.07 | $117 |
| 99215 Office E&M - Established | Office | 995 | 221 | $126.07 | $125K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 770 | 14 | $0.75 | $577 |
| 96375 Injection Administration | Office | 627 | 45 | $10.75 | $6,740 |
| 96372 Injection Administration | Office | 587 | 69 | $9.99 | $5,865 |
| 96413 Chemotherapy Administration | Office | 560 | 63 | $87.07 | $49K |
| 99214 Office E&M - Established | Office | 377 | 248 | $85.74 | $32K |
By year: 2022 $5.9M for 293,285 services; 2023 $5.4M for 271,627 services; 2024 $4.0M for 238,778 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,646 | 321 | $8.51 | $14K |
Medicare prescription drug claims, 2024
In 2024, the drug Jack E Saux III prescribed most often to Medicare patients was Letrozole, with 203 prescriptions and refills. In total Jack E Saux III wrote 1,890 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 203 | 429 | 55 | $3,892 |
| Tamoxifen Citrate Generic | 190 | 354 | 44 | $4,775 |
| Gabapentin Generic | 93 | 107 | 22 | $1,242 |
| Eliquis Apixaban | 57 | 92 | 15 | $52K |
| Prednisone Generic | 51 | 64 | 17 | $182 |
| Exemestane Generic | 46 | 68 | 11 | $3,578 |
| Acyclovir Generic | 45 | 58 | Under 11 | $462 |
| Ondansetron Odt Ondansetron | 45 | 45 | 18 | $1,104 |
| Ibrance Palbociclib | 43 | 43 | Under 11 | $715K |
| Abiraterone Acetate Generic | 42 | 42 | Under 11 | $135K |
| Tagrisso Osimertinib Mesylate | 37 | 37 | Under 11 | $577K |
| Calquence Acalabrutinib Maleate | 33 | 33 | Under 11 | $323K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 32 | 32 | 25 | $658 |
| Valacyclovir Valacyclovir Hcl | 32 | 40 | Under 11 | $1,019 |
| Escitalopram Oxalate Generic | 31 | 37 | Under 11 | $165 |
Brand drugs: 484 claims; generic drugs: 1,406 claims; opioid claims: 57.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jack E Saux III $2,913 ($2,913 in general payments such as food, travel and fees) from 38 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $260.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $260 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $228 |
| Daiichi Sankyo Inc. 4568.T | 7 | $210 |
| Janssen Biotech, Inc. JNJ | 7 | $192 |
| Pfizer Inc. PFE | 11 | $185 |
| Merck Sharp & Dohme LLC MRK | 4 | $182 |
| Celgene Corporation BMY | 9 | $167 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $124 |
| Gilead Sciences, Inc. GILD | 5 | $111 |
| Genentech USA, Inc. ROG.SW | 6 | $109 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.